BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 26951846)

  • 1. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Kim JM; Jeong HJ; Bae YJ; Park SY; Kim E; Kang SY; Oh ES; Kim KJ; Jeon B; Kim SE; Cho ZH; Kim YB
    Parkinsonism Relat Disord; 2016 May; 26():47-54. PubMed ID: 26951846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With (123) I-FP-CIT SPECT.
    Bae YJ; Kim JM; Kim E; Lee KM; Kang SY; Park HS; Kim KJ; Kim YE; Oh ES; Yun JY; Kim JS; Jeong HJ; Jeon B; Kim SE
    Mov Disord; 2016 May; 31(5):684-92. PubMed ID: 26990970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism.
    Sugiyama A; Sato N; Kimura Y; Ota M; Maekawa T; Sone D; Enokizono M; Murata M; Matsuda H; Kuwabara S
    Parkinsonism Relat Disord; 2018 Mar; 48():10-16. PubMed ID: 29279191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism.
    Zhao XJ; Niu XY; You HY; Zhou M; Ji XB; Liu Y; Wu L; Ding XL
    Curr Med Sci; 2019 Oct; 39(5):831-835. PubMed ID: 31612404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism.
    Reiter E; Mueller C; Pinter B; Krismer F; Scherfler C; Esterhammer R; Kremser C; Schocke M; Wenning GK; Poewe W; Seppi K
    Mov Disord; 2015 Jul; 30(8):1068-76. PubMed ID: 25773707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy.
    Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC
    Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Swallow tail sign on susceptibility map-weighted imaging (SMWI) for disease diagnosing and severity evaluating in parkinsonism.
    Liu X; Wang N; Chen C; Wu PY; Piao S; Geng D; Li Y
    Acta Radiol; 2021 Feb; 62(2):234-242. PubMed ID: 32380911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative susceptibility mapping in atypical Parkinsonisms.
    Mazzucchi S; Frosini D; Costagli M; Del Prete E; Donatelli G; Cecchi P; Migaleddu G; Bonuccelli U; Ceravolo R; Cosottini M
    Neuroimage Clin; 2019; 24():101999. PubMed ID: 31539801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study.
    Ofori E; Krismer F; Burciu RG; Pasternak O; McCracken JL; Lewis MM; Du G; McFarland NR; Okun MS; Poewe W; Mueller C; Gizewski ER; Schocke M; Kremser C; Li H; Huang X; Seppi K; Vaillancourt DE
    Mov Disord; 2017 Oct; 32(10):1457-1464. PubMed ID: 28714593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Extrastriatal
    Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [No Abstract]   [Full Text] [Related]  

  • 13. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
    Pirker W; Asenbaum S; Bencsits G; Prayer D; Gerschlager W; Deecke L; Brücke T
    Mov Disord; 2000 Nov; 15(6):1158-67. PubMed ID: 11104200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrastriatal
    Nicastro N; Fleury V; Broc N; Burkhard PR; Garibotto V
    Parkinsonism Relat Disord; 2020 Sep; 78():38-43. PubMed ID: 32698058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Substantia Nigra Hyperintensity at 3.0-T MR Imaging in Idiopathic REM Sleep Behavior Disorder: Comparison with
    Bae YJ; Kim JM; Kim KJ; Kim E; Park HS; Kang SY; Yoon IY; Lee JY; Jeon B; Kim SE
    Radiology; 2018 Apr; 287(1):285-293. PubMed ID: 29232183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
    Yoshita M; Hayashi M; Hirai S
    Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
    Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
    J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism.
    Bae YJ; Song YS; Kim JM; Choi BS; Nam Y; Choi JH; Lee WW; Kim JH
    AJNR Am J Neuroradiol; 2021 Apr; 42(4):681-687. PubMed ID: 33509919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manual MRI morphometry in Parkinsonian syndromes.
    Möller L; Kassubek J; Südmeyer M; Hilker R; Hattingen E; Egger K; Amtage F; Pinkhardt EH; Respondek G; Stamelou M; Möller F; Schnitzler A; Oertel WH; Knake S; Huppertz HJ; Höglinger GU
    Mov Disord; 2017 May; 32(5):778-782. PubMed ID: 28150443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
    Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
    Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.